Donald Zinn Email & Phone Number

Richland, Mi, Us

Dijon, Bourgogne, Fr

Crossject has developed a needle-free auto-injector platform capable of delivery from the dermis to intramuscular for almost any liquid drug in 1/10th of a second. Human factor studies have demonstrated that naive users can successfully utilize the device greater than 99% of the time. The device has been selected by BARDA for the Strategic National Stockpile for these reasons and its unprecedented reliability, surpassing the FDA's 5-9"s. Our portfolio of near market drug device combinations include Midazolam for Epilepsy, Hydrocortisone for Adrenal Crisis, Epinephrine for Anaphylaxis, Terbutaline for Asthma Exacerbations and Naloxone for Opioid Overdose. Lastly Crossject can increase your market share by garnering the needle phobic population, 10-20% of unfilled scripts, by placing your injectable in our device, this includes the successful delivery of small molecules, MAbs, Fusion Proteins, and DNA based vaccines.

New York, Ny, Us

GLG is the world’s leading platform connecting business to insights. Clients utilize GLG’s 650,000 member-experts to provide insights. Expertise includes business and scientific insights into the oncology, infectious disease, bone disease and biofilm spaces of the pharmaceutical, biotech and medical device industries.

Laupheim, Baden-Württemberg, De

Head of US innovation, member of international innovation team spearheading global corporate expansion. Prepare and present company at various international pharmaceutical conferences (JP Morgan Healthcare Conference, Biotech Showcase, RESI, N.Y. Oncology Investors Conference) optimize presentations, script talking points, identify optimal strategic partners for potential investment or business engagement. Develop and implement company innovation plan concerning: increasing EBIT by 25% over 5 years, develop alternative business relationships with biotechnology companies, feasibility and planning for corporate venture capital. Laid off due to Corona Virus pandemic

Grosse Pointe Farms, Mi, Us

Bozeman, Montana, Us

Worldwide Business Development

An Apjohn Group discovery stage biotechnology company developing unique peptides for the treatment of osteoporosis, osteoarthritis, accelerated fracture healing, and other bone related diseases. Company turned its focus to Muscular Dystrophy an area in which I do not have expertise.President & CEO & Member of the Board of Directors , Vice President of Business DevelopmentSenior executive officer developing and implementing the strategic direction and day-to-day operations of the company. Responsibilities include business development, negotiating alliances and collaborations with pharmaceutical and biotechnology companies, evaluating transactions and fundraising. Heavily involved in negotiating the in-licensing and out-licensing of company technology. Manage and mentor employees. Oversee outside consultants and contractors on outsourcing projects. Present company capabilities at fund raising and business development conferences.

Allendale, Mi, Us

Four-year public university in Western Michigan providing a fully accredited liberal arts undergraduate and graduate education for more than 24,000 students.

Allendale, Mi, Us

Teach General Biology. Develop and implement teaching techniques that include interactive learning, laboratory techniques, laboratory equipment use and utilize audiovisual and computer technology in ways that enhance learning. Curriculum development and revision, committee membership, teaching symposium and textbook edit and selection. Advise students on curriculum, academic programs, employment and career goals, and other matters, as appropriate. Engage in professional development activities that maintain expertise in the field of Biological Sciences, Biology Education, and instructional strategies. Demonstrate a commitment to Learning College Principles. Integrate professional expertise within the greater community.

Successful business accelerator with accomplished team comprised primarily of former Upjohn senior executives. Group launches life science companies focused on pharmaceuticals and medical devices. Executive In Residence (EIR) April 2007 - January 2008Responsibilities included evaluate, critical assessment and selection of innovative pharmaceutical and biological business ideas for launch. Advising Apjohn Group members on all aspects of start-up businesses, fundraising, presentation and business development strategies. Joined as Executive in Residence and placed as CEO of Aursos, an Apjohn Group start-up company (see above

Assessed potential to in-license technologies, including technical probability of success and potential market applications. Co-developed joint ventures and business plan. Managed the day-to-day operations. Presented company to angel and venture capital firms for potential investment.

VC financed by Oxford Bioscience Partners, involved in the in silico discovery and development of first generation, novel disease modifying and disease reversing therapeutics for the treatment of cardiovascular disease.Privately held biopharmaceutical company, venture financed by Oxford Bioscience Partners, involved in the in silico discovery and development of first generation novel cardiovascular disease modifying and disease reversing therapeutics. Responsibilities included co-development of the business plan, including resource allocation, budgets, competitive analysis and market research. Developed communications and information technology strategy, installation and implementation. Managed the day-to-day operations and general administration of the company, managed IT, administrative, facilities and scientific staff. Established human resource functions including hiring plan, benefits and 401(k) plan. Assisted in pre-clinical drug development including cardiovascular dog model devices. Assisted in the marketing of the company to venture capital firms for continued investment, acted as VC liaison to Oxford Bioscience Partners.

Laboratory Manager, All aspects of preclinical antiretroviral research,Managed all aspects of a cutting edge laboratory facility. Developed method for transcutaneous transfection of Langerhans cells for T cell mediated immunization of murine & non-human primates as a model for SHIV & HIV vaccines. Assisted in all aspects of preclinical, phase one and two human clinical trials. Structured Genetic Immunity for-profit corporate spin-out from RIGHT (see below)

Vice President of Operations, Co-Founder, Member of the Board of Directors, Treasurer, Tax Matters Partner, Genetic Immunity, LLC, Georgetown University Medical School, Washington, DC. Co-founded a pharmaceutical research and drug development company for the treatment and prevention of viral diseases. Company currently headquartered in Budapest, Hungary. GI is conducting multiple phase 2 human trials of its lead product DermaVir, a combination plasmid DNA based HIV vaccine and transdermal drug delivery system I co-developed. Company products include DNA based retroviral vaccines and dendritic cell targeted gene delivery systems. Responsibilities included: Business plan development, resource allocation, competitive intelligence and budgets. Fundraising including two private placement offerings personally attracting 95% of the total investors and 98% of the total investment. Co-developed an International Monetary Fund (IMF) proposal for initial clinical trials.

research programs covering a range of clinical topics including infectious disease, trauma medicine, health maintenance and cancer.; included quantifying the ubiquitin conjugating enzymes in immortalized cell lines through the use of biochemical and molecular techniques, conjugation and degradation of topoisomerase 1 and ubiquitin as influenced by the antitumor drug camptothecin. Performed experimental design, manuscript development and editing, general laboratory organization and maintenance.

Arlington, Virginia, Us

US Army Infantry, 3-64 Armor, Infantry support (11C), AFRC Services Staff

Education record

Bachelors Of Science, Biological Sciences